Artificial Intelligence

Laboratory technology
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Charles River #Collaboration #DNA technology #High throughput screening #Medicinal chemistry #Partnership #Pioneering Medicines

Partners enter multi-programme drug discovery agreement

Charles River Laboratories and Pioneering Medicines have entered a multi-programme agreement that gives Pioneering Medicines access to artificial intelligence (AI) model Logica.  Through the agreement, Pioneering Medicines will apply Logica across a portfolio of targets with the aim of creating optimised small molecules… Read More

#News

Big genomic data
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Bioinformatics #Collaboration #Genetics / genomics #Oncology #Partnership

Partners hope to “chart a new era of drug discovery”

A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments.  In this partnership, M2GEN will license its real-world data set (RWD) to Zephyr AI, while Zephyr AI will… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #Drug discovery #Machine learning #Medicinal chemistry #Webinar

Event: How to choose the most promising drug candidates

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More

Webinar date:
#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Events #Interview #SLAS2023

Acquiring deeper insights and acceleration with AI

At IBM Research, a group of scientists and researchers from around the globe is working to support the power of the scientific method to invent what’s next for IBM, its clients, and the world. Joshua Smith, PhD, IBM TJ Watson Research Center, speaks with DDW’s Megan Thomas about AI, and… Read More

#Exclusive Content

Tumour microenvironment
#Absci #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Oncology #St John’s Cancer Institute #Tumours

Partners use AI to speed up development of cancer therapies

AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies.   The companies will use Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to identify new… Read More

#Cancer Research #News

Businesswomen shaking hands
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Envision Pharma #Life sciences #Mergers and acquisitions #OKRA.ai

Envision Pharma Group acquires OKRA.ai

Envision Pharma Group has acquired OKRA.ai, a provider of artificial intelligence (AI) services for the pharmaceutical and life sciences industry. “We are delighted to welcome OKRA.ai into the Envision family,” said Meg Heim, CEO, Envision Pharma Group. “The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Data science #Drug development #Drug discovery #Pharmaceuticals

AI is critical to solving new complexities in drug discovery

Listen to this article on the DDW Podcast: Andrew A Radin Chief Executive Officer of Aria Pharmaceuticals, on the critical use of artificial intelligence in solving some of drug discovery’s most new and complex challenges. Basic research and new technologies are uncovering insights every day that build on our understanding of human… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #Drug discovery #Machine learning #Medicinal chemistry #Webinar

Learn how to choose the best drug candidates from your hit list

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More

Webinar date:
#News

ChatGPT
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Computational chemistry #Drug development #Drug discovery #Drug targets #Regulatory #Technology

Four ways ChatGPT could impact drug discovery

It’s impossible to be online and not hear about ChatGPT, the controversial chatbot launched by OpenAI in November 2022. Here, DDW’s Diana Spencer takes a look at the ways ChatGPT and technology like it could change the future of drug discovery and development. Chat Generative Pre-Trained Transformer (or ChatGPT) is… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #Drug discovery #Machine learning #Medicinal chemistry #Webinar

How to choose the most promising drug candidates from your hit list

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More

Webinar date:
#News

microRNA
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Funding #Investment #Machine learning #Molecular Biology #RNA #Start-ups

$35 million to advance AI-driven RNA structure platform

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round.  The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO… Read More

#Business & Investment #News #Start-up Zone

Luchen Li, wearing the sensor suit, and Professor Aldo Faisal.
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trials #Imperial College London #Movement disorders #Rare disease #Wearable tech

AI and wearable tech could speed up drug development

A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.   By combining human movement data gathered from wearable tech with a powerful new medical AI technology, the team were able to significantly increase the efficiency… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Covid-19 #Immunology / Virology & Vaccines

AI use in repurposing drugs for Covid-19

Listen to this article on the DDW podcast: In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Clinical trials revealed eight out of nine predictions were correct. Here Imran S Haque, VP Data Science at Recursion describes the journey of the AI platform behind those predictions. The Covid-19… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer drug targets #Cancer research #Collaboration #Oncology #Partnership

AI-powered cancer simulations enable drug targeting

Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases.   The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199.   CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. Read More

#Business & Investment #Cancer Research #News

Baby on a respirator - RSV
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Covid-19 #Immunology / Virology & Vaccines #Influenza #OneThree #Poolbeg Pharma #Respiratory syncytial virus

AI identifies drug candidates for respiratory syncytial virus

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV.  The AI programme, part of a collaboration between Poolbeg Pharma and OneThree, uses Poolbeg’s RSV human challenge… Read More

#Editor's Choice #News

Protein
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #BioInnovation Institute #Biologics / Biotechnology #Investment #Proteins #Start-ups

Therapeutic protein project joins Bio Studio programme

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of… Read More

#News #Start-up Zone